Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ, Ito T, Kambarov Y, Llorca PM, Oliveira-Maia AJ, Messer T, Mulhern-Haughey S, Rive B, von Holt C, Young AH, Godinov Y; ESCAPE-TRD Investigators. Reif A, et al. Among authors: llorca pm. N Engl J Med. 2023 Oct 5;389(14):1298-1309. doi: 10.1056/NEJMoa2304145. N Engl J Med. 2023. PMID: 37792613 Free article. Clinical Trial.
Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.
Young AH, Llorca PM, Fagiolini A, Falkai P, Cardoner N, Nielsen RE, Blomqvist O, Godinov Y, Rive B, Diels J, Mulhern-Haughey S, Reif A. Young AH, et al. Among authors: llorca pm. Br J Psychiatry. 2025 Feb;226(2):72-78. doi: 10.1192/bjp.2024.124. Epub 2024 Dec 2. Br J Psychiatry. 2025. PMID: 39618237 Clinical Trial.
Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial - ERRATUM.
Young AH, Llorca PM, Fagiolini A, Falkai P, Cardoner N, Nielsen RE, Blomqvist O, Godinov Y, Rive B, Diels J, Mulhern-Haughey S, Reif A. Young AH, et al. Among authors: llorca pm. Br J Psychiatry. 2025 Jun 9:1-2. doi: 10.1192/bjp.2025.10308. Online ahead of print. Br J Psychiatry. 2025. PMID: 40488357 No abstract available.
Clinical and inflammatory markers associated with metabolic dysfunction-associated fatty liver disease in a cohort of individuals with chronic schizophrenia (FACE-SZ).
Tokarski R, Barbosa S, Pignon B, Aouizerate B, Andrieu C, Andre M, Boukouaci W, Capdevielle D, Chereau I, Dondé C, Kobayashi JC, Dorey JM, Dubertret C, Fakra E, Fond G, Goze T, Leignier S, Llorca PM, Mallet J, Misdrahi D, Oriol N, Rey R, Roux P, Schürhoff F, Schorr B, Szöke A, Urbach M, Very E, Wu CL; FACE-SZ group; Leboyer M, Tamouza R, Godin O. Tokarski R, et al. Among authors: llorca pm. J Psychosom Res. 2025 Jun 22;195:112192. doi: 10.1016/j.jpsychores.2025.112192. Online ahead of print. J Psychosom Res. 2025. PMID: 40561671 Free article.
Substance use disorders in outpatients with bipolar disorder and pain complaints.
Chabert J, Icick R, Cabé J, Moisset X, Godin O, Gard S, Aouizerate B, Loftus J, Aubin V, Lefrere A, Dubertret C, Roux P, Polosan M, Schwitzer T, Etain B, Moirand R, Olié E, Haffen E, Leboyer M, Courtet P, Walter M, Bouaziz N, Yrondi A, Belzeaux R; Bipolar-Addiction workgroup; FACE-BD collaborators; Llorca PM, Brousse G, Samalin L. Chabert J, et al. Among authors: llorca pm. J Affect Disord. 2025 Jun 17:119693. doi: 10.1016/j.jad.2025.119693. Online ahead of print. J Affect Disord. 2025. PMID: 40553735 Free article.
Pro-inflammatory processes and metabolic syndrome: combined risk of resistance to treatment in patients with schizophrenia from the FACE-SZ cohort.
Saitoh K, Lajnef M, Boukouaci W, Andre M, Andrieu C, Aouizerate B, Barau C, Bouassida J, Capdevielle D, Chereau I, Clauss-Kobayashi J, Coulon N, Dorey JM, Dubertret C, Fakra E, Fond G, Goze T, Le Corvoisier P, Leignier S, Llorca PM, Mallet J, Misdrahi D, Oriol N, Pignon B, Rey R, Roux P, Schürhoff F, Schorr B, Urbach M, Very E, Wu CL; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) collaborators; Leboyer M, Godin O, Tamouza R. Saitoh K, et al. Among authors: llorca pm. Psychiatry Res. 2025 Aug;350:116557. doi: 10.1016/j.psychres.2025.116557. Epub 2025 May 20. Psychiatry Res. 2025. PMID: 40460461
[Building precision psychiatry: why and how?].
Chaumette B, Yrondi A, Godin O, Krebs MO, Boyer L, Samalin L, Llorca PM, Leboyer M. Chaumette B, et al. Among authors: llorca pm. Med Sci (Paris). 2025 May;41(5):416-424. doi: 10.1051/medsci/2025072. Epub 2025 May 26. Med Sci (Paris). 2025. PMID: 40418003 Review. French.
Exploring the Association Between Residual Mood Symptoms and Self-Reported Side Effects in the Euthymic Phase of Bipolar Disorders: A Cross-Sectional Network Analysis.
Vidal N, Brunet-Gouet E, Frileux S, Aubin V, Belzeaux R, Courtet P, D'Amato T, Dubertret C, Etain B, Gard S, Haffen E, Januel D, Leboyer M, Lefrere A, Llorca PM, Marlinge E, Olié E, Polosan M, Schwan R, Walter M; The FACE-BD (FondaMental Academic Centers of Expertise for Bipolar Disorders) group; Passerieux C, Roux P. Vidal N, et al. Among authors: llorca pm. Depress Anxiety. 2024 Oct 24;2024:3375145. doi: 10.1155/2024/3375145. eCollection 2024. Depress Anxiety. 2024. PMID: 40226716 Free PMC article.
517 results